• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[奥地利风湿病学会、肺病学会、传染病学会、皮肤病学会和胃肠病学会关于潜伏性结核病管理及生物和靶向合成改善病情抗风湿药(DMARDs)相关应用的全国共识声明]

[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)].

作者信息

Rath Eva, Bonelli Michael, Duftner Christina, Gruber Johann, Mandl Peter, Moazedi-Furst Florentine, Pieringer Herwig, Puchner Rudolf, Flick Holger, Salzer Helmut J F, Weiss Günter, Winkler Stefan, Skvara Hans, Moschen Alexander, Hofer Harald, Feurstein Julia, Sautner Judith

机构信息

Österreichische Gesellschaft für Rheumatologie und Rehabilitation (ÖGR), Wien, Österreich.

1. Medizinische Abteilung, Hanusch Krankenhaus, Wien, Österreich.

出版信息

Z Rheumatol. 2023 Mar;82(2):163-174. doi: 10.1007/s00393-022-01274-6. Epub 2022 Nov 7.

DOI:10.1007/s00393-022-01274-6
PMID:36342525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9981509/
Abstract

This nationwide Austrian consensus statement summarizes the recommendations on the management of latent tuberculosis by treatment with biologic and targeted synthetic DMARDs. The essential questions with respect to screening and preventive treatment were discussed by experts from the disciplines of rheumatology, pneumology, infectious diseases, dermatology and gastroenterology, based on the available data, and then a joint consensus was formed by agreement. This involved a differentiated discussion on the various forms of treatment, and clear recommendations were formulated.

摘要

这份奥地利全国性共识声明总结了关于使用生物制剂和靶向合成抗风湿药物治疗潜伏性结核病的管理建议。来自风湿病学、肺病学、传染病学、皮肤病学和胃肠病学领域的专家根据现有数据讨论了筛查和预防性治疗的关键问题,然后通过协商达成了联合共识。这涉及对各种治疗形式的差异化讨论,并制定了明确的建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c57e/9981509/d0c635c5eb3c/393_2022_1274_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c57e/9981509/d0c635c5eb3c/393_2022_1274_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c57e/9981509/d0c635c5eb3c/393_2022_1274_Fig1_HTML.jpg

相似文献

1
[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)].[奥地利风湿病学会、肺病学会、传染病学会、皮肤病学会和胃肠病学会关于潜伏性结核病管理及生物和靶向合成改善病情抗风湿药(DMARDs)相关应用的全国共识声明]
Z Rheumatol. 2023 Mar;82(2):163-174. doi: 10.1007/s00393-022-01274-6. Epub 2022 Nov 7.
2
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).奥地利风湿病学会、肺病学会、传染病学会、皮肤病学会和胃肠病学会关于潜伏性结核病管理以及生物制剂和靶向合成的疾病修饰抗风湿药物(DMARDs)相关使用的国家共识声明。
Wien Klin Wochenschr. 2022 Nov;134(21-22):751-765. doi: 10.1007/s00508-022-02062-7. Epub 2022 Aug 29.
3
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015年美国风湿病学会类风湿关节炎治疗指南
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.
4
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.西班牙风湿病学会关于类风湿关节炎生物治疗应用的共识声明2014年更新版
Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6.
5
Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.西班牙风湿病学会关于生物制剂和合成靶向治疗药物在类风湿关节炎中应用的共识声明更新。
Reumatol Clin (Engl Ed). 2024 Oct;20(8):423-439. doi: 10.1016/j.reumae.2024.09.002. Epub 2024 Sep 27.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略:2019 年更新版(使用合成和生物疾病修正抗风湿药物)
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
7
2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.2016年更新的泰国风湿病协会关于类风湿关节炎患者使用生物制剂和靶向合成改善病情抗风湿药物的建议。
Int J Rheum Dis. 2017 Sep;20(9):1166-1184. doi: 10.1111/1756-185X.13130. Epub 2017 Jul 21.
8
Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.科威特风湿病学会 2018 年类风湿关节炎患者治疗建议。
Rheumatol Int. 2019 Sep;39(9):1483-1497. doi: 10.1007/s00296-019-04372-y. Epub 2019 Jul 15.
9
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.EULAR 推荐的类风湿关节炎治疗策略:2016 年更新版
Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.
10
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2021 年美国风湿病学会类风湿关节炎治疗指南。
Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8.

引用本文的文献

1
Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork.儿童银屑病的系统治疗——跨学科团队协作算法建议
J Clin Med. 2024 Oct 22;13(21):6307. doi: 10.3390/jcm13216307.
2
[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].[基础疾病和免疫抑制对炎性风湿性疾病免疫能力的影响]
Z Rheumatol. 2024 Mar;83(2):87-97. doi: 10.1007/s00393-023-01408-4. Epub 2023 Aug 29.

本文引用的文献

1
[Not Available].[无可用内容]。
J Dtsch Dermatol Ges. 2021 Jun;19(6):934-951. doi: 10.1111/ddg.14508_g.
2
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2021年美国风湿病学会类风湿关节炎治疗指南
Arthritis Rheumatol. 2021 Jul;73(7):1108-1123. doi: 10.1002/art.41752. Epub 2021 Jun 8.
3
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.阿尼鲁单抗治疗活动期系统性红斑狼疮患者的安全性特征:II 期和 III 期临床试验的综合分析。
Lupus Sci Med. 2021 Feb;8(1). doi: 10.1136/lupus-2020-000464.
4
Avacopan for the Treatment of ANCA-Associated Vasculitis.阿伐考潘治疗抗中性粒细胞胞浆抗体相关性血管炎。
N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386.
5
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.司库奇尤单抗治疗银屑病、银屑病关节炎或强直性脊柱炎患者结核再激活的相关性。
JAMA Dermatol. 2021 Jan 1;157(1):43-51. doi: 10.1001/jamadermatol.2020.3257.
6
Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.银屑病患者使用白细胞介素(IL)-17 和 IL-23 抑制剂治疗后结核再激活的风险 - 是时候改变观念了。
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):824-834. doi: 10.1111/jdv.16866. Epub 2020 Sep 1.
7
Impact and prognosis of the expression of IFN-α among tuberculosis patients.干扰素-α在结核病患者中的表达影响及预后
PLoS One. 2020 Jul 15;15(7):e0235488. doi: 10.1371/journal.pone.0235488. eCollection 2020.
8
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors.结核病以及除肿瘤坏死因子抑制剂之外的靶向合成或生物性改善病情抗风湿药。
Ther Adv Musculoskelet Dis. 2020 Jun 22;12:1759720X20930116. doi: 10.1177/1759720X20930116. eCollection 2020.
9
Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.Janus 激酶抑制剂治疗类风湿关节炎患者的结核病风险的系统评价
Expert Opin Drug Saf. 2020 Jul;19(7):861-872. doi: 10.1080/14740338.2020.1774550. Epub 2020 Jun 17.
10
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.罗莫单抗治疗低骨密度的疗效和安全性:一项系统评价和荟萃分析。
Clin Rheumatol. 2020 Nov;39(11):3261-3276. doi: 10.1007/s10067-020-04948-1. Epub 2020 May 8.